Nephros Announces Release of DialyPath, a qPCR-based, Real-time, On-site Endotoxin Assay for Dialysis Water

SOUTH ORANGE, NJ – ( NewMediaWire ) – October 13, 2020 –  Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced availability of DialyPath(TM), an assay that estimates endotoxin levels in dialysis water samples.

Water sampling is generally required in dialysis clinics to ensure that no waterborne contamination is present. Of particular interest are endotoxins, which are gram-negative bacterial fragments that can cause inflammation and other complications in dialysis patients. DialyPath is an on-site test that measures endotoxin levels in about two hours.

DialyPath results correlate highly (R2>0.95) with data from the limulus amebocyte lysate (LAL) assay, currently the industry standard for endotoxin measurement (EU/ml). DialyPath uses qPCR technology to quantify DNA target segments in a water sample, which are matched to a DNA segment that is found in all

Read More